BliNK Biomedical Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 11
Employees
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $1.84M
Latest Deal Amount
  • Investors
  • 3

BliNK Biomedical General Information

Description

Developer of a B cell technology designed to assist in the selection and isolation of specific antibody-producing cells. The company's platform constitutes an efficient and deep mining process which isolates antibody producing cells for difficult targets from B cells of many species, such as man, mouse, rabbit, dog, enabling researchers to identify unique therapeutic antibodies.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 17 Boulevard Cieussa
  • 13007 Marseille
  • France
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

BliNK Biomedical Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC (Series A) 12-Jul-2016 $1.84M 00.000 Completed Generating Revenue
1. Later Stage VC (Series A) 11-Dec-2014 00.000 00.000 Completed Generating Revenue
To view BliNK Biomedical’s complete valuation and funding history, request access »

BliNK Biomedical Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a B cell technology designed to assist in the selection and isolation of specific antibody-producing cells.
Biotechnology
Marseille, France
11 As of 2016
00.000
00000000000 00.000

0000000

dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sin
0000 000000000
Philadelphia, PA
00 As of 0000
00000
0000 0000-00-00
00000000000 00000

00000 00

lore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliqui
0000 000000000
Geneva, Switzerland
00 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BliNK Biomedical Competitors (93)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Tmunity Venture Capital-Backed Philadelphia, PA 00 00000 00000000000 00000
00000 00000 000000 Venture Capital-Backed Geneva, Switzerland 00 00000 00000000000 00000
000000 0000000 Venture Capital-Backed Zurich, Switzerland 00 000.00 000000 0
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
000000000000 Formerly VC-backed Beijing, China 000 00000 00000000 00000
You’re viewing 5 of 93 competitors. Get the full list »

BliNK Biomedical Patents

BliNK Biomedical Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3072394-A1 Cd96-binding agents as immunomodulators Pending 11-Aug-2017 000000000
AU-2018315432-A1 Cd96-binding agents as immunomodulators Pending 11-Aug-2017 000000000
JP-2020530859-A Cd96 binder as an immunomodulator Pending 11-Aug-2017 000000000
EP-3664843-A1 Cd96-binding agents as immunomodulators Pending 11-Aug-2017 C07K16/2803

BliNK Biomedical Executive Team (2)

Name Title Board Seat Contact Info
Jack Elands Ph.D Chief Executive Officer, Chairman & Manager
You’re viewing 1 of 2 executive team members. Get the full list »

BliNK Biomedical Board Members (8)

Name Representing Role Since
Franck Grimaud Valneva Board Member 000 0000
Jack Elands Ph.D BliNK Biomedical Chief Executive Officer, Chairman & Manager 000 0000
Michael Owen Ph.D Self Board Member 000 0000
Thierry Laugel Ph.D Kurma Partners Board Member 000 0000
You’re viewing 4 of 8 board members. Get the full list »

BliNK Biomedical Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BliNK Biomedical Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Cancer Research UK Venture Capital Minority 000 0000 000000 0
Kurma Partners Venture Capital Minority 000 0000 000000 0
Valneva Corporation Minority 000 0000 000000 0
To view BliNK Biomedical’s complete investors history, request access »